Chevron Ruling Could Chill FDA’s Public Health Efforts, Stem AI, LDT Regulation

By Jessica Karins, Sigi Ris / June 28, 2024 at 6:10 PM

The Supreme Court’s decision Friday (June 28) overturning the Chevron doctrine could force FDA to spend more time considering the political and legal environment surrounding regulatory efforts -- hamstringing its ability to take bold action on public health priorities -- given that courts can no longer defer to federal agencies’ interpretation of vague statutes, regulatory experts say.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.